Skip to main content

Advertisement

Log in

The Clinical Relevance of Anti-DFS70 Autoantibodies

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Despite all the progress in the establishment of specific autoantibody assays, screening for antinuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells for quality-oriented laboratory diagnosis of ANA associated rheumatic diseases (AARD) remains indispensable but is not without limitations. Recent data on the relevance of the dense fine speckled (DFS) pattern and anti-DFS70 antibodies disclosed novel possibilities to optimize the serological stepwise diagnostics of AARD. The DFS pattern on HEp-2 cells is well differentiated from the classic “homogeneous” ANA pattern associated with dsDNA antibodies. This is the most frequent pattern in high titer ANA-positive healthy persons. The most characteristic ANA specificity associated with DFS pattern is the anti-DFS70 antibody (synonym LEDGF antibody). The prevalence of anti-DFS70 antibodies in AARD patients is significantly lower compared with the prevalence in ANA-positive healthy persons. There is a negative association between anti-DFS70 antibodies and AARD, especially if no concomitant AARD-specific autoantibodies are found. Isolated anti-DFS70 antibodies are detectable in less than 1 % of AARD but are detectable in 2–22 % of healthy persons. In the presence of an isolated anti-DFS70 antibody, the posttest probability for AARD is reduced significantly. The significance of anti-DFS70 antibodies as a criterion that helps to exclude AARD is also confirmed by follow-up studies on anti-DFS70 antibodies of positive, healthy individuals, who did not develop any AARD during a 4 year observation period. Consequently, anti-DFS70 antibodies are valuable novel biomarkers for better interpretation of positive ANA in cases of negative AARD-associated autoantibodies and should be integrated in modified test algorithms to avoid unnecessary referrals and examinations of ANA-positive persons.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. doi:10.1155/2014/315179

    Google Scholar 

  2. Mahler M, Fritzler MJ (2010) Epitope specificity and significance in systemic autoimmune diseases. Ann NY Acad Sci 1183:267–287

    Article  CAS  PubMed  Google Scholar 

  3. Bogdanos DP, Invernizzi P, MacKay IR, Vergani D (2008) Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 14:3374–3387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Alvarez F, Berg PA, Bianchi FB et al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938

    Article  CAS  PubMed  Google Scholar 

  5. Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69:1420–1422

    Article  CAS  PubMed  Google Scholar 

  6. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  PubMed  Google Scholar 

  7. Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 64:2677–2686

    Article  PubMed  PubMed Central  Google Scholar 

  8. Costenbader KH, Schur PH (2015) We need better classification and terminology for “people at high risk of or in the process of developing lupus”. Arthritis Care Res 67:593–596

    Article  Google Scholar 

  9. Ugarte-Gil MF, Alarcón GS (2016) Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis? Arthritis Care Res 68:285–287

    Article  Google Scholar 

  10. Mahler M, Hanly JG, Fritzler MJ (2012) Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun 11:642–645

    Article  CAS  Google Scholar 

  11. Hiemann R, Büttner T, Krieger T, Roggenbuck D, Sack U, Conrad K (2009) Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimm Rev 9:17–22

    Article  CAS  Google Scholar 

  12. Ochs RL, Stein TW, Peebles CL, Gittes RF, Tan EM (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592

    CAS  PubMed  Google Scholar 

  13. Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM (2000) Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 105:1211–1220

    Article  CAS  PubMed  Google Scholar 

  14. Tan EM, Zhang J (2008) Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222:328–340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Narciso-Schiavon JL, Freire FCF, Suarez MM, Ferrari MVO, Scanhola GQ, Schiavon LD, Carvalho FRJ, Ferraz MLG, Silva AEB (2009) Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 21:440–446

    Article  PubMed  Google Scholar 

  16. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in healthy individuals. Arthritis Rheum 40:1601–1611

    Article  CAS  PubMed  Google Scholar 

  17. Conrad K, Schößler W, Hiepe F, Fritzler M (2015) Autoantibodies in systemic diseases - A diagnostic reference, 3rd edn. Pabst Science Publishers, Lengerich

    Google Scholar 

  18. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann NY Acad Sci 1173:166–173. doi:10.1111/j.1749-6632.2009.04735

    Article  CAS  PubMed  Google Scholar 

  19. Wiik AS, Høier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290

    Article  CAS  PubMed  Google Scholar 

  20. Dellavance A, Viana VST, Leon EP, Bonfa ESDO, Andrade LEC, Leser PG (2005) The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 32:2144–2149

    CAS  PubMed  Google Scholar 

  21. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200

    Article  CAS  PubMed  Google Scholar 

  22. Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LEC (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. doi:10.3389/fimmu.2015.00412

    Google Scholar 

  23. Fritzler MJ (2016) Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev 15:272–289. doi:10.1016/j.autrev.2015.12.002

    Article  PubMed  Google Scholar 

  24. Ge H, Si Y, Roeder RG (1998) Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 17:6723–6729

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Singh DP, Ohguro N, Kikuchi T, Sueno T, Reddy VN, Yuge K et al (2000) Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem Biophys Res Commun 267:373–381

    Article  CAS  PubMed  Google Scholar 

  26. Shinohara T, Singh DP, Fatma N (2002) LEDGF, a survival factor, activates stress-related genes. Prog Retin Eye Res 21:341–358

    Article  CAS  PubMed  Google Scholar 

  27. Kuwabara N, Itoh Y, Igarshi T, Fukunaga Y (2009) Autoantibodies to lens epithelium-derived growth factor/transcription co-activator P75 (LEDGF/P75) in children with chronic nonspecific complaints and with positive antinuclear antibodies. Autoimmun 42:492–496

    Article  CAS  Google Scholar 

  28. Yamada K, Senju S, Shinohara T, Nakatsura T, Murata Y et al (2001) Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett 78:161–168

    Article  CAS  PubMed  Google Scholar 

  29. Chin MS, Caruso RC, Detrick B, Hooks JJ (2006) Autoantibodies to p75/LEDGF, a cell survival factor, found in patients with atypical retinal degeneration. J Autoimmun 27:17–27

    Article  CAS  PubMed  Google Scholar 

  30. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z et al (2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 278:33528–33539

    Article  CAS  PubMed  Google Scholar 

  31. Ogawa Y, Sugiura K, Watanabe A, Kunimatsu M, Mishima M, Tomita Y, Muroa Y (2004) Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 23:221–231

    Article  CAS  PubMed  Google Scholar 

  32. Sugiura K, Muro Y, Nishizawa Y, Okamoto M, Shinohara T, Tomita Y, Usukura J (2007) LEDGF/DFS70, a major autoantigen of atopic dermatitis, is a component of keratohyalin granules. J Invest Dermatol 127:75–80

  33. Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, Nagasaka T, Tomita Y, Muro Y (2004) Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun 23:257–266

  34. Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ et al (2005) Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 62:14–26

    Article  CAS  PubMed  Google Scholar 

  35. Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N, Singh DP, Ko V, Shinohara T (2002) Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmun 35:319–327

    Article  CAS  Google Scholar 

  36. Baid R, Scheinman RI, Shinohara T, Singh DP, Kompella UB (2011) LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells. PLoS One 6:e24616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Watanabe M, Muro Y, Sugiura K, Tomita Y (2011) IgE and IgG4 autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmun 44:511–519

    Article  CAS  Google Scholar 

  38. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, Ferguson DJ, Villalta D, Bizzaro N, Hanly JG, Fritzler MJ (2012) Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 39:2104–2110

    Article  PubMed  Google Scholar 

  39. O’Rourke DJ, Di Johnson DA, Caiazzo RJ Jr, Nelson JC, Ure D, O’Leary MP, Richie JP, Liu BCS (2012) Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chem Acta 413:561–567. doi:10.1016/j.cca.2011.11.027

    Article  Google Scholar 

  40. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G (2011) A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Translational Med 9:43. doi:10.1186/1479-5876-9-43

    Article  CAS  Google Scholar 

  41. Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY (2014) Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens. J Immunol Res. doi:10.1155/2014/827827

    Google Scholar 

  42. Basu A, Rojas H, Banerjee H, Cabrera IB, Perez KY, De León M, Casiano CA (2012) Expression of the Stress Response Oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One. doi:10.1371/journal.pone.0030132

    Google Scholar 

  43. Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M et al (2014) Oncogenic human papilloma viruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog 10:e1003957. doi:10.1371/journal.ppat.1003957

    Article  PubMed  PubMed Central  Google Scholar 

  44. Bizzaro N, Tonutti E, Visentini D, Alessio MG, Platzgummer S, Morozzi G, Antico A, Villalta D, Piller-Roner S, Vigevani E (2007) Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann NY Acad Sci 1107:174–183

    Article  CAS  PubMed  Google Scholar 

  45. Pramanik B (2014) Diagnosis of systemic lupus erythematosus in an unusual presentation: what a primary care physician should know. Curr Rheumat Rev 10:81–86

    Article  Google Scholar 

  46. Calixto OJ, Franco JS, Anaya JM (2014) Lupus mimickers. Autoimmun Rev 13:865–872

    Article  CAS  PubMed  Google Scholar 

  47. Aslanidis S, Pyrpasopoulou A, Kontotasios K, Doumas S, Zamboulis C (2008) Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? Europ J Int Med 19:314–318

    Article  Google Scholar 

  48. Belder-Preston D, Pound CM, Jurencak R (2011) An atypical presentation of Kikuchi-Fujimoto disease mimicking systemic lupus erythematosus: case report and literature review. Open J Ped 1:67–71. doi:10.4236/ojped.2011.14016

    Article  Google Scholar 

  49. Solomon DH, Kavanaugh AJ, Schur PH, The American College Of Rheumatology Ad Hoc Committee On Immunologic Testing Guidelines (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care Res 47:434–444

    Article  Google Scholar 

  50. Van den Hoogen F, Khanna D, Fransen J (2013) 2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthr Rheum 65:2737–2747

    Article  Google Scholar 

  51. Leroy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

    CAS  PubMed  Google Scholar 

  52. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr (2000) Systemic sclerosis sine scleroderma. Demographic, Clinical, and Serologic Features and Survival in Forty-Eight Patients. Arthritis Rheum 43:444–451

    Article  CAS  PubMed  Google Scholar 

  53. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos MH, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman WH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, Mcnamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan JS, Daniels TE for the Sjögren’s International Collaborative Clinical Alliance (Sicca) Research Groups (2012) American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res 64:475–487

    Article  CAS  Google Scholar 

  55. Bournia VK, Vlachoyiannopoulos PG (2012) Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 39:15–26

    Article  PubMed  Google Scholar 

  56. Muro Y, Sugiura K, Morita Y, Tomita Y (2008) High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 17:171–176

    Article  CAS  PubMed  Google Scholar 

  57. Röber N, Höpner U, Aringer M, Sebastian S, Gräßler A, Lüthke K, Unger L, Mahler M, Conrad K (2015) Anti-DFS70 antibodies without disease specific antibodies help to rule out ANA associated rheumatic diseases. In: Conrad K, Chan EKL, Andrade LEC, Steiner G, Pruijn GJM, Shoenfeld Y (eds) From Autoantibody Research to Standardized Diagnostic Assays in the Management of Human Diseases. Pabst Science Publishers, Lengerich, pp 173–174

    Google Scholar 

  58. Mimori T, Imura Y, Nakashima R, Yoshifuji H (2007) Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opinion Rheumat 19:523–529

    Article  Google Scholar 

  59. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2015) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clinic Rev Allerg Immunol. doi:10.1007/s12016-015-8510-y

    Google Scholar 

  60. Reichlin M, Arnett AC Jr (1994) Multiplicity of antibodies in myositis sera. Arthritis Rheum 27:1150–1156

    Article  Google Scholar 

  61. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70:360–374

    Article  CAS  PubMed  Google Scholar 

  62. Sato S, Kuwana M, Hirakata M, Nogi S, Sasaki N, Chinen N, Honda K, Saito E, Wakabayashi T, Chiho Yamada C, Suzuki Y (2014) Clinical phenotype of Japanese patients with dermatomyositis - Classification based on dermatomyositis-specific autoantibodies. Open J Rheumatol Autoimm Dis 4:124–130

    Article  Google Scholar 

  63. Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459–467

    Article  CAS  PubMed  Google Scholar 

  64. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M (2013) Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol 40:92–93

    Article  CAS  PubMed  Google Scholar 

  65. Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620

    CAS  PubMed  Google Scholar 

  66. Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S (2014) The diagnosis and classification of undifferentiated connective tissue Diseases. J Autoimmun 48–49:50–52

    Article  PubMed  Google Scholar 

  67. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum 62:2569–2581

    Article  PubMed  Google Scholar 

  68. Lormeau C, Falgarone G, Roulot D, Boissier MC (2006) Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 73:633–638

    Article  PubMed  Google Scholar 

  69. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900

    Article  CAS  PubMed  Google Scholar 

  70. Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, Mcmillan JD, Horneff G, Assassi S, Charles J, Salazar G, Mayes MD, Silverman ED, Klien-Gitelman M, Lee T, Brunner HI, Reed AM, Fritzler MJ (2015) Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. J Rheumatol 42:12. doi:10.3899/jrheum.150567

    Article  Google Scholar 

  71. Nilsson AV, Voss A, Lillevang ST (2015) DFS70 autoantibodies are rare in healthy Danish individuals but may still serve as a diagnostic aid. Scand J Immunol 82:547–548

    Article  CAS  PubMed  Google Scholar 

  72. Kang SY, Lee WI (2009) Clinical significance of dense fine speckled pattern in anti-nuclear antibody test using indirect immunofluorescence method. Korean J Lab Med 29:145–151

    Article  CAS  PubMed  Google Scholar 

  73. Marlet J, Ankri A, Charuel JL, Ghillani-Dalbin P, Perret A, Martin-Toutain I, Haroche J, Amoura Z, Musset L, Miyara M (2015) Thrombophilia associated with anti-DFS70 autoantibodies. PLoS One 10:e0138671. doi:10.1371/journal.pone.0138671

    Article  PubMed  PubMed Central  Google Scholar 

  74. Goto N, Sugiura K, Ogawa Y, Watanabe A, Onouchi H, Tomita Y, Muro Y (2006) Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies. J Autoimmun 26:42–51

    Article  CAS  PubMed  Google Scholar 

  75. Pazini AM, Fleck J, dos Santos RS, Beck ST (2010) Clinical relevance and frequency of cytoplasmic and nuclear dense fine speckled patterns observed in ANA-HEp-2. Bras J Rheumatol 50:655–664

    Google Scholar 

  76. Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, Amoura Z, Musset L, Mahler M (2013) Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. doi:10.1155/2013/703759

    PubMed  PubMed Central  Google Scholar 

  77. Itoh Y, Hamada H, Imai T, Seki T, Igarashi T, Yuge K, Fukunaga Y, Yamamoto M (1997) Antinuclear antibodies in children with chronic nonspecific complaints. Autoimmun 25:243–250

    Article  CAS  Google Scholar 

  78. Fitch-Rogalsky C, Steber W, Mahler M, Lupton T, Martin L, Barr SG, Mosher DP, Wick J, Fritzler MJ (2014) Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One. doi:10.1371/journal.pone.0093812

    PubMed  PubMed Central  Google Scholar 

  79. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  80. Bizzaro N, Tonutti E, Tampoia M, Infantino M, Cucchiaro F, Pesente F, Morozzi G, Fabris M, Villalta D, Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine (2015) Specific chemoluminescence and immunoadsorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta 451:271–277. doi:10.1016/j.cca.2015.10.008

    Article  CAS  PubMed  Google Scholar 

  81. Bentow C, Rosemblum R, Correia P, Karayev E, Karayev D, Williams D, Kulczycka J, Fritzler MJ, Mahler M (2016) Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus 25:897–904

  82. Bizzaro N, Tonutti E, Villalta D (2011) Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEp-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 63:4036–4037

    Article  PubMed  Google Scholar 

  83. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LE, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EK, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23

    Article  CAS  PubMed  Google Scholar 

  84. Lee H, Kim Y, Han K, Oh EJ (2016) Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense finde speckled pattern on HEp-2 cell. Scand J Rheumatol 45:122–128

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karsten Conrad.

Ethics declarations

Conflict of Interest

Michael Mahler is an employee of Inova Diagnostics and the inventor of the NOVA Lite HEp-2 method but does not receive any license compensation for the product. However, this did not affect the planning and writing of this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Conrad, K., Röber, N., Andrade, L.E.C. et al. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clinic Rev Allerg Immunol 52, 202–216 (2017). https://doi.org/10.1007/s12016-016-8564-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8564-5

Keywords

Navigation